Description_x000D_ Application_x000D_ SB-431542 was used to study the correlation of platelet-derived growth factor receptor B expression and TGF-β pathway activation in colorectal tumor cells. It was used to study the role of TGF-β signaling in modulation of extracellular matrix and myoblast differentiation._x000D_ Packaging_x000D_ 5 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ SB-431542 inhibits the TGF-β-mediated activation of SMAD proteins, expression of collagen and fibronectin, cell proliferation and cell motility. It does not inhibit kinases that are activated in response to serum or stress such as ERK, p38 or JNK._x000D_ Potent and selective inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors._x000D_ Features and Benefits_x000D_ This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Glaxo­Smith­Kline